Cargando…
P913: LOW-DOSE BELANTAMAB MAFODOTIN (BELAMAF) IN COMBINATION WITH NIROGACESTAT VS BELAMAF MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1/2 DREAMM-5 PLATFORM SUB-STUDY 3
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431067/ http://dx.doi.org/10.1097/01.HS9.0000970556.97221.22 |
| _version_ | 1785091111509819392 |
|---|---|
| author | Callander, Natalie Richardson, Paul Hus, Marek Ribrag, Vincent Martinez-Lopez, Joaquín Kim, Kihyun Hoon Lee, Jae Dimopoulos, Meletios A. Schjesvold, Fredrik Facon, Thierry Jo, Jae-Cheol Min, Chang-Ki Mielnik, Michał Cheng, Shinta Smith, Mary Breitbach, Caroline J. Brawley, Chris Sembhi, Harjeet Lamacchia, John Grosicki, Sebastian |
| author_facet | Callander, Natalie Richardson, Paul Hus, Marek Ribrag, Vincent Martinez-Lopez, Joaquín Kim, Kihyun Hoon Lee, Jae Dimopoulos, Meletios A. Schjesvold, Fredrik Facon, Thierry Jo, Jae-Cheol Min, Chang-Ki Mielnik, Michał Cheng, Shinta Smith, Mary Breitbach, Caroline J. Brawley, Chris Sembhi, Harjeet Lamacchia, John Grosicki, Sebastian |
| author_sort | Callander, Natalie |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10431067 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104310672023-08-17 P913: LOW-DOSE BELANTAMAB MAFODOTIN (BELAMAF) IN COMBINATION WITH NIROGACESTAT VS BELAMAF MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1/2 DREAMM-5 PLATFORM SUB-STUDY 3 Callander, Natalie Richardson, Paul Hus, Marek Ribrag, Vincent Martinez-Lopez, Joaquín Kim, Kihyun Hoon Lee, Jae Dimopoulos, Meletios A. Schjesvold, Fredrik Facon, Thierry Jo, Jae-Cheol Min, Chang-Ki Mielnik, Michał Cheng, Shinta Smith, Mary Breitbach, Caroline J. Brawley, Chris Sembhi, Harjeet Lamacchia, John Grosicki, Sebastian Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10431067/ http://dx.doi.org/10.1097/01.HS9.0000970556.97221.22 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Callander, Natalie Richardson, Paul Hus, Marek Ribrag, Vincent Martinez-Lopez, Joaquín Kim, Kihyun Hoon Lee, Jae Dimopoulos, Meletios A. Schjesvold, Fredrik Facon, Thierry Jo, Jae-Cheol Min, Chang-Ki Mielnik, Michał Cheng, Shinta Smith, Mary Breitbach, Caroline J. Brawley, Chris Sembhi, Harjeet Lamacchia, John Grosicki, Sebastian P913: LOW-DOSE BELANTAMAB MAFODOTIN (BELAMAF) IN COMBINATION WITH NIROGACESTAT VS BELAMAF MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1/2 DREAMM-5 PLATFORM SUB-STUDY 3 |
| title | P913: LOW-DOSE BELANTAMAB MAFODOTIN (BELAMAF) IN COMBINATION WITH NIROGACESTAT VS BELAMAF MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1/2 DREAMM-5 PLATFORM SUB-STUDY 3 |
| title_full | P913: LOW-DOSE BELANTAMAB MAFODOTIN (BELAMAF) IN COMBINATION WITH NIROGACESTAT VS BELAMAF MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1/2 DREAMM-5 PLATFORM SUB-STUDY 3 |
| title_fullStr | P913: LOW-DOSE BELANTAMAB MAFODOTIN (BELAMAF) IN COMBINATION WITH NIROGACESTAT VS BELAMAF MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1/2 DREAMM-5 PLATFORM SUB-STUDY 3 |
| title_full_unstemmed | P913: LOW-DOSE BELANTAMAB MAFODOTIN (BELAMAF) IN COMBINATION WITH NIROGACESTAT VS BELAMAF MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1/2 DREAMM-5 PLATFORM SUB-STUDY 3 |
| title_short | P913: LOW-DOSE BELANTAMAB MAFODOTIN (BELAMAF) IN COMBINATION WITH NIROGACESTAT VS BELAMAF MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1/2 DREAMM-5 PLATFORM SUB-STUDY 3 |
| title_sort | p913: low-dose belantamab mafodotin (belamaf) in combination with nirogacestat vs belamaf monotherapy in patients with relapsed/refractory multiple myeloma (rrmm): phase 1/2 dreamm-5 platform sub-study 3 |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431067/ http://dx.doi.org/10.1097/01.HS9.0000970556.97221.22 |
| work_keys_str_mv | AT callandernatalie p913lowdosebelantamabmafodotinbelamafincombinationwithnirogacestatvsbelamafmonotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmphase12dreamm5platformsubstudy3 AT richardsonpaul p913lowdosebelantamabmafodotinbelamafincombinationwithnirogacestatvsbelamafmonotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmphase12dreamm5platformsubstudy3 AT husmarek p913lowdosebelantamabmafodotinbelamafincombinationwithnirogacestatvsbelamafmonotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmphase12dreamm5platformsubstudy3 AT ribragvincent p913lowdosebelantamabmafodotinbelamafincombinationwithnirogacestatvsbelamafmonotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmphase12dreamm5platformsubstudy3 AT martinezlopezjoaquin p913lowdosebelantamabmafodotinbelamafincombinationwithnirogacestatvsbelamafmonotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmphase12dreamm5platformsubstudy3 AT kimkihyun p913lowdosebelantamabmafodotinbelamafincombinationwithnirogacestatvsbelamafmonotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmphase12dreamm5platformsubstudy3 AT hoonleejae p913lowdosebelantamabmafodotinbelamafincombinationwithnirogacestatvsbelamafmonotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmphase12dreamm5platformsubstudy3 AT dimopoulosmeletiosa p913lowdosebelantamabmafodotinbelamafincombinationwithnirogacestatvsbelamafmonotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmphase12dreamm5platformsubstudy3 AT schjesvoldfredrik p913lowdosebelantamabmafodotinbelamafincombinationwithnirogacestatvsbelamafmonotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmphase12dreamm5platformsubstudy3 AT faconthierry p913lowdosebelantamabmafodotinbelamafincombinationwithnirogacestatvsbelamafmonotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmphase12dreamm5platformsubstudy3 AT jojaecheol p913lowdosebelantamabmafodotinbelamafincombinationwithnirogacestatvsbelamafmonotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmphase12dreamm5platformsubstudy3 AT minchangki p913lowdosebelantamabmafodotinbelamafincombinationwithnirogacestatvsbelamafmonotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmphase12dreamm5platformsubstudy3 AT mielnikmichał p913lowdosebelantamabmafodotinbelamafincombinationwithnirogacestatvsbelamafmonotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmphase12dreamm5platformsubstudy3 AT chengshinta p913lowdosebelantamabmafodotinbelamafincombinationwithnirogacestatvsbelamafmonotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmphase12dreamm5platformsubstudy3 AT smithmary p913lowdosebelantamabmafodotinbelamafincombinationwithnirogacestatvsbelamafmonotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmphase12dreamm5platformsubstudy3 AT breitbachcarolinej p913lowdosebelantamabmafodotinbelamafincombinationwithnirogacestatvsbelamafmonotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmphase12dreamm5platformsubstudy3 AT brawleychris p913lowdosebelantamabmafodotinbelamafincombinationwithnirogacestatvsbelamafmonotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmphase12dreamm5platformsubstudy3 AT sembhiharjeet p913lowdosebelantamabmafodotinbelamafincombinationwithnirogacestatvsbelamafmonotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmphase12dreamm5platformsubstudy3 AT lamacchiajohn p913lowdosebelantamabmafodotinbelamafincombinationwithnirogacestatvsbelamafmonotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmphase12dreamm5platformsubstudy3 AT grosickisebastian p913lowdosebelantamabmafodotinbelamafincombinationwithnirogacestatvsbelamafmonotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmphase12dreamm5platformsubstudy3 |